# Immunosuppression in Amyotrophic Lateral Sclerosis (ALS)

> **NCT01884571** · PHASE2 · COMPLETED · sponsor: **Emory University** · enrollment: 31 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis (ALS)

## Interventions

- **DRUG:** Basiliximab
- **DRUG:** Methylprednisolone
- **DRUG:** Prednisone
- **DRUG:** Tacrolimus
- **DRUG:** Mycophenolate mofetil

## Key facts

- **NCT ID:** NCT01884571
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2016-01
- **Final completion:** 2016-01
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2017-11-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01884571

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01884571, "Immunosuppression in Amyotrophic Lateral Sclerosis (ALS)". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT01884571. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*